Omega-3 polyunsaturated fatty acids

Natural fatty acids involved in human physiological processes.

Phase of research

Potential treatment - clinical evidence

How it helps

Unknown

Drug status

Natural product

1
Supporting references
0
Contradictory references
5
AI-suggested references
1
Clinical trials

General information

Omega-3 polyunsaturated fatty acids responsible for multiple cellular functions. They are essential for multiple processes in the human body (e.g. proper function of nervous system, blood clotting, or glucose tolerance). Omega-3 polyunsaturated fatty acids are investigated for their anti-inflammatory and antioxidant properties (Gammone et al., 2019).

Omega-3 polyunsaturated fatty acids on DrugBank
Omega-3 polyunsaturated fatty acids on Wikipedia


Synonyms

Omega-3 fatty acids; ω-3 fatty acids; n3-PUFAs

 


Supporting references

Link Tested on Impact factor Notes Publication date
The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial
Small molecule Critical severity Randomized controlled double-blind trial Mixed substance
Critically ill COVID-19 patients 4.12

The 1-month survival rate was higher in the treatment group compared to the control. Positive effects on acidosis and renal parameters in critically ill COVID-19 patients were observed, as well. (No significant difference was observed in several other clinical parameters, however.) Sample size: 28 + 73 placebo (final analyses). Dosage: 1000 mg daily enterally (400 mg EPAs and 200 mg DHAs) for 14 days.


Mar/29/2021

AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04647604 Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - Completed Phase 2 Jun/23/2020 Jul/07/2021
  • Alternative id - 2020-002293-28
  • Interventions - Drug: Omegaven®|Drug: Sodium chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Karolinska Universitetssjuhuset, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 23
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Changes in inflammatory biomarkers|Changes in proresolving mediators|Changes in fatty acids in the erythrocyte fraction|Changes in cardiac biomarkers|Changes in biomarkers of organ damage|Changes in thrombosis parameters|Changes in coagulation parameters|Changes in markers of infection|Changes in infection load|Changes in clinical parameters|Length of hospital stay|Complications